Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

被引：0
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 06期
关键词：
Hemolytic anemia; pyruvate kinase deficiency; mitapivat; sickle cell disease; thalassemia; red blood cells; hemoglobin;
D O I：
10.2174/0929867330666230430002709
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Mitapivat is an orally bioavailable small molecule allosteric activator of pyruvate kinase. It was approved by the US FDA on February 17, 2022, and the European Union in November 2022 for the treatment of hemolytic anemia in adult patients with pyruvate kinase deficiency. In this short perspective, physicochemical properties, synthesis, dosage and administration, mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, and adverse reactions of mitapivat are described.
引用
收藏
页码：683 / 687
页数：5
相关论文
共 50 条
  • [1] An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency
    Song, Andrew B.
    Al-Samkari, Hanny
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (10) : 875 - 885
  • [2] Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency
    Wills, Josef
    Horenstein, Melissa
    Kim, Alicia
    Silva, Matthew A.
    Dima, Lorena
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (05) : E433 - E438
  • [3] A SYSTEMATIC REVIEW OF EFFICACY AND SAFETY OF MITAPIVAT TO TREAT HEMOLYTIC ANEMIA IN PYRUVATE KINASE DEFICIENCY
    Veeranki, P.
    Rayapureddy, G.
    Kummari, P.
    Mir, J.
    Manne, M.
    Chidirala, S.
    Hyderboini, R.
    Rajput, A.
    Kohli, I. S.
    Goyal, R.
    Aggarwal, A.
    Tanushree, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S23 - S23
  • [4] Mitapivat for treatment of pyruvate kinase deficiency
    Costa, Fernando F.
    [J]. LANCET HAEMATOLOGY, 2022, 9 (10): : E708 - E709
  • [5] Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults
    Zhuang-Yan, Amy
    Shirley, Matt
    [J]. DRUGS, 2023, 83 (17) : 1613 - 1620
  • [6] Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults
    Amy Zhuang-Yan
    Matt Shirley
    [J]. Drugs, 2023, 83 : 1613 - 1620
  • [7] Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
    Al-Samkari, Hanny
    van Beers, Eduard J.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [8] HEREDITARY NONSPHEROCYTIC HEMOLYTIC ANEMIA WITH PYRUVATE KINASE DEFICIENCY
    TANAKA, KR
    VALENTINE, WN
    SCHNEIDER, AS
    [J]. ANNALS OF INTERNAL MEDICINE, 1963, 58 (04) : 732 - +
  • [9] ROENTGENOGRAPHIC MANIFESTATIONS OF PYRUVATE KINASE DEFICIENCY HEMOLYTIC ANEMIA
    BECKER, MH
    GENIESER, NB
    PIOMELLI, S
    DOVE, D
    MENDOZA, RD
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY RADIUM THERAPY AND NUCLEAR MEDICINE, 1971, 113 (03): : 491 - &
  • [10] Mitapivat versus Placebo for Pyruvate Kinase Deficiency
    Al-Samkari, Hanny
    Galacteros, Frederic
    Glenthoj, Andreas
    Rothman, Jennifer A.
    Andres, Oliver
    Grace, Rachael F.
    Morado-Arias, Marta
    Layton, D. Mark
    Onodera, Koichi
    Verhovsek, Madeleine
    Barcellini, Wilma
    Chonat, Satheesh
    Judge, Malia P.
    Zagadailov, Erin
    Xu, Rengyi
    Hawkins, Peter
    Beynon, Vanessa
    Gheuens, Sarah
    van Beers, Eduard J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15): : 1432 - 1442
12345